EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, , Groningen, The Netherlands.
R V
RV
Moerman
S
S
Arends
P M
PM
Meiners
E
E
Brouwer
F K L
FK
Spijkervet
F G M
FG
Kroese
A
A
Vissink
H
H
Bootsma
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069283:Rituximab; D012720:Severity of Illness Index; D012859:Sjogren's Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab
B cells; Disease Activity; SjÃgren's Syndrome